CNCR vs NHF

Loncar Cancer Immunotherapy ETF

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

NexPoint Strategic Opportunities Fund

NexPoint Strategic Opportunities Fund is a closed ended balanced mutual fund launched by Highland Capital Management, L.P. It is managed by Nexpoint Advisors, L.P. The fund invests in the fixed income markets of the United States. It invests in companies across broadly diversified sectors to construct its portfolio. The fund typically invests in senior loans, secured and unsecured floating and fixed rate loans, bonds, debt obligations of stressed, distressed, and bankrupt issuers, mortgage-backed securities, asset-backed securities, and collateralized debt obligations with a primary focus on below investment grade debt and equity securities. It employs a quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Dow Jones Credit Suisse Hedge Fund and the HFRX Global Hedge Fund. It was formerly known as NexPoint Credit Strategies Fund. NexPoint Strategic Opportunities Fund was formed on June 1, 2006 and is domiciled in the United States.